LYNTONIX was awarded the "2025 National Innovation Excellence Award" by the Biotechnology and Medical Technology Policy Research Center Foundation, recognizing LYNTONIX's achievements and results in core technologies, commercial applications, and intellectual property patent layout.

According to research findings, oral administration of LTX-568 for 30 min significantly relieved visceral pain in irritable bowel syndrome (IBS) animal models compared to existing IBS drugs. Moreover, after 10 consecutive days of treatment, the abnormal proliferation of nerve fibers in intestinal mucosal layer and the overexpression of serotonin 7 receptor were back to normal levels. These findings have been published in academic journals.

In 2024 and 2025, LTX-568 was granted the patents in Europe and China, respectively. Together with the existing patents in United States, Japan, South Korea, and Taiwan, the patent portfolio covers the major IBS pharmaceutical markets worldwide. In 2025, LYNTONIX was established, and the licensing of LTX-568 was successfully completed.